A chance for treatment - immunotherapy in the prevention and treatment of chronic fungal infections
Frank L. van de Veerdonk Radboud Center for Infectious diseases (RCI) ESCMID eLibrary © by author Candida infections
Mucocutaneous infections Invasive candidiasis
Th
ESCMIDT helper cells eLibraryPhagocytes © by author Chronic Candida infection
30% to 50% of individuals are colonized with Candida at any given moment, but only rarely causing mucosal infections
Even more rarely are these infections chronic
However, several clinical syndromes have been described with chronic CandidaESCMIDinfections eLibrary © by author Mucosal host defence against Candida
ESCMID eLibrary Nature Microbiol. Reviews 2012 © by author Mucosal host defence against Candida
ESCMID eLibrary Nature Microbiol. Reviews 2012 © by author Chronic Candida infections
Hyper IgE syndrome (HIES)
Dectin-1/CARD9 deficiency
Chronic mucocutaneous candidiasis
(STAT1 GOF, APECED, IL-17F, IL-17R) ESCMID eLibrary © by author Characteristics of Hyper IgE syndrome
ESCMID eLibrary © by author Loss of function STAT3 mutation
Heterozygous mutation in STAT3 ESCMIDDominant negative eLibrary © by author Cytokine signalling
INTERLEUKIN-6/23
IL-6/IL-23 RECEPTOR
STAT3 phosphorylation
IL-17 ESCMID eLibrary PMN Levy and Loomis et al, NEJM 2007 © by author Th17 deficiency in HIES
IL-17
ESCMID eLibrary IFNg van de Veerdonk et al, Clin Exp Immunol© 2010by author Chronic Candida infections
Hyper IgE syndrome (HIES)
Dectin-1/CARD9 deficiency
Chronic mucocutaneous candidiasis
ESCMID eLibrary © by author Dectin-1/CARD9 recognition pathway
Candida Cell wall
Mannans
ESCMIDb-glucans eLibrary © by author Dectin-1 deficiency
- Recurrent vulvovaginal infections - Onychomycosis
ESCMID eLibrary Ferwerda et al. NEJM 2009 © by author Decreased Th17 response
ESCMID eLibrary © by author Dectin-1 deficiency dectin-1 con Loss of a Glutamic acid that binds calcium
dectin-1 pat
Folding/transport is disturbed no expression of dectin-1 at ESCMID eLibrarythe cell membrane © by author CARD9 deficiency
- Increased susceptibility to both mucocutaneous and systemic Candida infections (brain) - Deficient Th17 response
ESCMID eLibrary Glocker et al. NEJM 2009 © by author CLR-CARD9 pathway
ESCMID eLibrary © by author Chronic Candida infections
Hyper IgE syndrome (HIES)
Dectin-1/CARD9 deficiency
Chronic mucocutaneous candidiasis
ESCMID eLibrary © by author APECED
AIRE gene: autoimmune regulator on chr. 21
Expression in thymus: ESCMID eLibraryimportant for depletion of autoreactive cells Nature Genetics 1997 © by author Auto-antibodies against IL-17
ESCMID eLibrary © by author Th17 deficiency: How important is IL-17 for controlling mucosal candidiasis?
ESCMID eLibrary © by author ESCMID eLibrary Autosomal recessive IL-17RA deficiency Autosomal dominant IL-17F deficiency © by author IL-17 signalling pathway
ESCMID eLibrary © by author IL-17 signalling pathway
ESCMID eLibrary © by author Family with autosomal dominant CMC
ESCMID eLibrary van de Veerdonk et al, NEJM 2011 © by author Chronic mucocutaneous candidiasis (CMC)
ESCMID CharleseLibrary Kirkpatrick © by author First documented CMC?
ESCMID eLibrary Ferdinand Bol, Vier regenten van het© Leprozenhuis, 1649by author First documented CMC?
ESCMID eLibrary Ferdinand Bol, Vier regenten van het© Leprozenhuis, 1649by author T helper cytokines
ESCMID eLibrary © by author Systematical approach
Neutrophil
Interleukin(IL) ESCMID-1 eLibrary TNF © by author Th1: defective IL-12 response
IL-12
Th1
ESCMID eLibraryIFN g © by author Th17: defective IL-23 response
IL-23
Th17
IL-17 ESCMID eLibraryIL-22 Van de Veerdonk et al, NEJM 2011 © by author Molecules shared by IL-12 and IL-23 pathways
Upstream Downstream
ESCMID eLibrary © by author Next generation sequencing
All exons from 100 selected genes
Mutation in STAT1 ESCMID eLibraryArg274Trp © by author Many more STAT1 mutations
ESCMID eLibrary © by author What is the mechanism leading to susceptibility to mucocutaneous candidiasis?
ESCMID eLibrary © by author STAT molecules
INTERLEUKINS
RECEPTOR
STAT phosphorylation
IL-17 ESCMID eLibrary Levy and Loomis, NEJM 2007 © by author STAT1 hyperphosphorylation
ESCMID eLibrary © by author Gain of function mutation
STAT1 hyperphosphorylation
ESCMID eLibrary Liu et al., JEM 2011 © by author Hypothesis Hypothesis
Th17 responses IFN type I and II IL-27
STAT1 GOF ESCMID eLibrary © by author Immunomodulatory options?
ESCMID eLibrary © by author Hypothesis
IL-23
Th17 STAT3
IL-17 ESCMID eLibrary © by author Hypothesis
IL-23
STAT1 GOF Th17 STAT3
IL-17 ESCMID eLibrary © by author HypothesisSTAT1 inhibitor (fludarabine) IL-23
STAT1 GOF Th17 STAT3
IL-17 ESCMID eLibrary © by author HypothesisSTAT1 inhibitor (fludarabine) IL-23
STAT1 GOF Th17 STAT3
IL-17 IL-22 ESCMID eLibrary © by author STAT1 GOF clinical phenotype - Chronic candida/trichophyton infection skin and mucosa (long known) - Severe disseminated cutaneous fusariosis - Disseminated endemic mycosis (Coccidioidomycosis and histoplasmosis) - Disseminated aspergillosis - Viral infections (herpes) - IPEX like syndrome - PD-L1 overexpression and decreased B cell survival - Progression to full SCID - Cerebral and pulmonary arterial aneurysms - Esophageal and oropharyngeal carcinomas - ESCMIDAutoimmune diseases (AHIA, autoimmune eLibrary hepatitis) © by author Hypothesis Hypothesis
Th17 responses IFN type I and II IL-27
STAT1 GOF
? ESCMIDWhat else….. eLibrary © by author Trained immunity
training (H3K4me3)
e
s
n priming Quintin et al., CHM, 2012
o
p
s
e
r
e
n
u homeostasis
m
m
i
tolerance (H3K4me3)
e
t
a Foster et al., Nature 2007
n
n i duration (days/weeks?)
primary secondary infESCMIDection infection eLibrary Saeed, Quintin et al, Science, 2014 © by author Hypothesis
b-glucan-induced Trained immunity
ESCMID eLibrary © by author Epigenetic modification by STAT1?
ESCMID eLibrary © by author Epigenetic modification by STAT1?
ESCMID eLibrary © by author Epigenetic modification by STAT1?
IL-23
Th17 STAT1 GOF STAT3
IL-17 ILESCMID-22 eLibrary © by author Hypothesis Another approach
Th17 responses IFN type I and II IL-27
STAT1 GOF ESCMID eLibrary © by author Ruxolitinib (JAK1/JAK2 inhibitor)
ESCMID eLibrary © by author ESCMID eLibrary © by author Ruxolitinib
STAT1
ESCMID eLibrary © by author Ruxolitinib
STAT1
ESCMID eLibrary © by author Take home messages
Dysregulated Th17 responses play a major role in chronic Candida infections
Restoring dysregulated STAT1-STAT3 activation in CMC: - Direct inhibition of STAT1 - Epigenetic modulation - Indirect via JAK inhibitors or anti-cytokine antibodies
Future:ESCMID gene surgery? eLibrary © by author University of Colorado Mark Gresnigt Tania Azam Katharina Becker Charles Dinarello Berenice Rosler Xiaowen Wang East Tennessee State University James Cheng David Williams Ralph Maas Sanne Smeekens Newcastle University UK Bart Ferwerda Desa Lilic Marije Oosting Gerben Ferwerda NIH Liesbeth Jacobs Ofer Zimmerman Alexander Hoischen Steven Holland Joris Veltman Jos van der Meer INSERM Leo Joosten Anne Puel Bart Jan Kullberg Mihai Netea Freiburg University ESCMIDBodo Grimbacher eLibrary © by author ESCMID eLibrary © by author